-
Akebia Q2 2026: Vafseo revenue $21.3M (+34% QoQ); net loss $8.9M
Vafseo net product revenue $21.3M in Q2 2026, up 34% from Q1; over 10,500 patients on therapy.
-
VOICE trial interim analysis shows Vafseo superior to ESA on composite endpoint; trial stopped
Win odds 1.16 (95% CI 1.06-1.28, p=0.0016) for all-cause mortality/hospitalization composite.
-
Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%
Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.
-
Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction
Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.
-
Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2
Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.
-
Akebia buys ADX-097 from Q32 Bio for $10M upfront (total up to $582M milestones); plans Phase 2 trials in 2026
Upfront $7M paid at closing, additional $3M due in 6 months; development milestones up to $94.5M and commercial milestones up to $487.5M, plus tiered royalties from low single to mid-teen %.
-
Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing
Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.
-
Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure
Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.
-
Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics
Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.
-
Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev
Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.
-
Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds
Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.
-
Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M
Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.
-
Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline
Expects existing cash and cash from ops to fund current plan for at least two years.
-
Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage
Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.
-
Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access
Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.
-
Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025
Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.
-
Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option
License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.
-
Akebia Q1 net loss narrows to $18M; Vafseo FDA approved, launch set for Jan 2025
Total revenues $32.6M (Q1 2024) vs $40.0M (Q1 2023); Auryxia net product revenues $31.0M vs $34.7M.
-
Akebia Therapeutics receives FDA approval for Vafseo (vadadustat) for dialysis patients
FDA approved Vafseo for anemia due to CKD in adults on dialysis ≥3 months; boxed warning for thrombosis risks.
-
Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer
CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.
-
Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27
Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.
-
Akebia extends separation dates for COO Dahan to June 28 and CLO Hadas to June 14
COO Michel Dahan's separation extended from March 22 to June 28, 2024.
-
Akebia secures $55M Kreos term loan, draws $37M initial, issues warrants at $1.30, repays Pharmakon debt
Initial draw of $37M under senior secured term loan; up to $55M total with two additional tranches contingent on vadadustat FDA approval and equity proceeds.
-
Akebia Q3 net loss $14.5M, Auryxia rev $40.1M, vadadustat PDUFA Mar 27, 2024
Net loss improved to $14.5M from $54.1M in Q3 2022; total revenue $42.0M, down from $48.7M.
-
Akebia extends loan maturity to March 2025, removes SOFR cap
Extended maturity of $35M Term Loans from Nov 2024 to March 31, 2025.
-
FDA accepts Akebia's resubmitted NDA for vadadustat; PDUFA date March 27, 2024
Resubmission classified as class 2 response; six-month review period from resubmission date.
-
Akebia reports Q2 net loss $11.2M, plans vadadustat NDA resubmission by Q3 end
Net product revenue Auryxia $42.2M (-2.5% YoY); reaffirms FY 2023 guidance $175-180M.
-
Akebia receives Nasdaq deficiency notice for late Q2 filing; plans to file by Aug 25
Form 10-Q for Q2 2023 not filed on time; Nasdaq gave non-compliance notice on Aug 11, 2023.
-
Akebia delays Form 10-Q filing due to accounting errors; reaffirms 2023 revenue guidance
Identified accounting errors in recording Auryxia return reserves, delaying Q2 2023 Form 10-Q filing.
-
CFO David Spellman resigns; Ellen Snow appointed as new CFO effective July 17, 2023
David Spellman resigns as CFO, effective June 23, 2023; will receive 12 months base salary continuation and COBRA reimbursement.